TIGERMED (03347) surged over 4%, reaching HK$43.9 by the time of writing, with a trading volume of HK$20.72 million. The company recently released its Q3 2025 financial report, showing total revenue of RMB5.026 billion for the first three quarters, a slight year-on-year decline of 0.82%, while net profit attributable to shareholders rose 25.45% to RMB1.02 billion.

In Q3 alone, revenue increased by 3.86% year-on-year to RMB1.775 billion, with net profit soaring 98.73% to RMB637 million. Huachuang Securities noted that the Q3 revenue growth marked a significant improvement compared to the 3.21% decline in H1.

The company's clinical trial-related and laboratory services remained stable, generating RMB1.71 billion (+3.1%) in H1, driven primarily by growth in its Site Management Organization (SMO) business. New SMO orders maintained double-digit growth, demonstrating strong resilience and promising prospects.

Looking ahead, as the industry recovers and order prices stabilize, TIGERMED's performance recovery is expected to continue.